Researchers test a method for delivering genetic material into the body to repair damaged heart muscle

A method for delivering genetic material to the body is being tested as a way to repair damaged heart muscle after a heart attack. The ground-breaking research is presented today at Frontiers in CardioVascular Biomedicine 2022, a scientific congress of the European Society of Cardiology (ESC).

The COVID-19 messenger RNA (mRNA) vaccines use lipid nanoparticles (tiny fat droplets) to deliver mRNA to the body's cells. This mRNA instructs the cells to manufacture a dummy spike protein on their surface to mimic the protein on the virus causing COVID-19. The body then mounts an immune response by creating antibodies which can be used if the individual becomes infected with the virus.

A similar method for mRNA delivery was used in the current study. However, instead of aiming for an immune response, the researchers' ultimate goal is to instruct the heart's cells to repair themselves after a heart attack.

This preliminary study was conducted to determine whether mRNA could be successfully delivered to the heart muscle in lipid nanoparticles. The researchers injected different formulations into the left ventricular wall of mouse hearts during open chest surgery under general anaesthesia. Twenty-four hours after administration, the mice were sacrificed and the location of mRNA translation was examined.

The researchers found that mRNA successfully reached the heart cells 24 hours after injection. However, despite injection into the heart, the highest levels of mRNA translation were found in cells of the liver and spleen.

High expression was expected in the liver, since it metabolises the lipid nanoparticles. Nonetheless, it was encouraging to see that there was mRNA translation in the heart tissue which means that lipid nanoparticles could work as delivery systems for mRNA therapy."

Dr. Clara Labonia, Study Author, University Medical Center Utrecht, the Netherlands

She concluded: "The next step of this research is to test more formulations and choose the one which most efficiently targets the heart tissue. We will then assess whether delivery of mRNA to mice with ischaemic hearts (resembling a heart attack) has any therapeutic effect."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Decoding the genetic roots of stroke and heart attack